search
Back to results

Extracorporeal Shock Wave Therapy Applied to the Plantar Region in Individuals With Hemiplegia

Primary Purpose

Extracorporeal Shock Wave Therapy, Kinaesthesia, Sensory Disorders

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
ESWT
Sponsored by
Firat University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Extracorporeal Shock Wave Therapy focused on measuring Extracorporeal Shock Wave Therapy, Kineaesthesia, Hemiplegia, Deep sense, Superficial sense

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • First-ever hemiplegia
  • Hemiplegia duration of at least 6 months
  • Ability to walk alone without an orthosis.

Exclusion Criteria:

  • Patients with ataxia, dystonia, or dyskinesia
  • Patients with dementia
  • Patients with bilateral hemiplegia
  • Taking antispastic drugs

Sites / Locations

  • Furkan Bilek

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

No Intervention

Arm Label

ESWT

Placebo

Arm Description

Patients assigned to the ESWT group received ESWT over the plantar fascia, three days/week, for six weeks. In addition patients participated additional in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.

Routine therapy Patients participated in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.

Outcomes

Primary Outcome Measures

Balance
Berg Balance Scale (BBS): The BBS is a 14-item test of functional balance, with each item rated out of 4 for a total score of 56. It assesses static balance in sitting and standing, as well as dynamic balance during transitions and while in standing. Individuals who are able to maintain their balance for each task score higher on this outcome.
Maximum plantar pressure
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure maximum plantar pressure
Static posture
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure static posture
Step cycle duration
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure step cycle duration
Single-support phase
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure single-support phase
Swing phase
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure swing phase
Step length
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure step length
Foot angle
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure foot angle
Cadence
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure cadence
Gait cycle distance
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure

Secondary Outcome Measures

Full Information

First Posted
April 16, 2022
Last Updated
April 28, 2022
Sponsor
Firat University
search

1. Study Identification

Unique Protocol Identification Number
NCT05360316
Brief Title
Extracorporeal Shock Wave Therapy Applied to the Plantar Region in Individuals With Hemiplegia
Official Title
The Effect of Extracorporeal Shock Wave Therapy Applied to the Plantar Region in Individuals With Hemiplegia on Mobility, Plantar Pressure Distribution and Sensory
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
January 4, 2020 (Actual)
Primary Completion Date
April 4, 2021 (Actual)
Study Completion Date
May 4, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Firat University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Sensory and balance losses occur in hemiplegic patients. In some patients, sensory and balance rehabilitations may vary depending on the treatment they receive, depending on the treatment. It is a fact that the affected anatomic neuronal regions can cause different damages for each person together with interneuronal relations. This study aims to sense sensation with Extracorporeal Shock Wave Therapy to be applied to the plantar region.
Detailed Description
Every year in England and Wales, 110,000 people experience first stroke and 30,000 people experience other stroke events following the first stroke. Stroke is one of the most important events causing severe distress and is shown as the third most common cause of death in England. Most of the health and social care resources budget uses it to meet the acute and chronic care of stroke patients. 5% of all hospital expenses are spent for the care of stroke patients. Stroke causes 88% of the death causes of the 65 and over life group and 10-12% of all deaths in industrial countries. Stroke can always be an obstacle in patients and cause them to need long-term care. After the stroke, patients apply to the hospital due to psychological, social and physical problems. The sudden loss of functionality creates strong stress not only in the patient but also in the family. Neurological damage can also become irreversible distress. Signs and symptoms related to stroke vary depending on the localization and severity of the damage. Stroke often results in paralysis of one side of the body. Paralysis of one side of the body occurs on the opposite side of the damaged side of the brain. Stopping blood flow to the brain causes focal function loss up to various levels in the patient. The most common motor is loss. Other neurological losses are visual, sensory, communicative, swallowing and perceptual problems. Kinesthesis and vibration losses are especially evident in the distal parts of the extremities. Kinesthesis and loss of position sense cause irregular and excessively flawed movements that are performed voluntarily with insufficient information about proprioception to the sensory cortex. Such patients are able to stand or walk, although they are not very balanced, as they can somewhat assess the position of their body parts with the sense of vision; but they have great difficulty walking in the dark. Shock waves have been used extensively to study their effects on sensory nerves and nerve endings. Application of 1000 impulses of shock waves (0.08 mJ/mm, 2.4 Hz) resulted in the degeneration of sensory nerve fibers and endings followed by reinnervation of the affected skin areas These changes were accompanied by the reversible and rapid loss of the immunohistochemical markers protein gene product 9.5 and calcitonin gene-related peptide. However, a second application of the same dose of shock waves had a cumulative effect on the treated nerves, leading to delayed reinnervation. It appears, therefore, that shock wave-treated nerves develop a "memory effect" after the first treatment, and Extracorporeal Shock Wave Therapy (ESWT) repeated shortly after the first treatment is not beneficial. It is expected that ESWT induces subtle changes in the affected neurons whose axons have been treated. Investigators detected an increased expression of activating transcription factor 3 (ATF-3) and growth-associated phosphoprotein 43 (GAP-43) in dorsal root ganglion neurons of shock wave-treated rats, indicating that the molecular changes after ESWT are not restricted to the treated axons: their cell bodies are also activated in a retrograde manner. The question remains open as to whether doses of ESWT in the therapeutic range would induce similar changes as the 2000 impulses applied in this study. ATF-3 and GAP-43 are markers thought to be associated with the activation of neurons and glial cells (Schwann cells) after peripheral nerve injuries. As regards the dose-effect relationship of ESWT on peripheral nerves, a large body of evidence suggests that shock wave doses greater than 900 impulses combined with a flux density of 0.08 mJ/mm2 induce damage to the affected nerves, manifested in impaired electrophysiological conduction parameters, a disrupted neurofilament staining pattern of the treated axons, and degeneration of the myelin sheaths at the levels of light and electron microscopy. These doses appeared to damage motor and sensory nerves equally. This experimental and clinical experience indicates that the therapeutically applicable dose for the promotion of nerve regeneration without side effects is likely to be lower than 500 impulses. The effect of such doses is highly dependent on the depth of the target tissue and the treated surface area. In this study, the effect of ESWT on sensory nerves will be used in individuals with hemiplegia. Thus, mobility and plantar region sensory development of plantar sensory stimulation will be evaluated in individuals with hemiplegia. A study specific to the literature will be presented by evaluating the effect of evaluation results on the function.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Extracorporeal Shock Wave Therapy, Kinaesthesia, Sensory Disorders
Keywords
Extracorporeal Shock Wave Therapy, Kineaesthesia, Hemiplegia, Deep sense, Superficial sense

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomized controlled, double blind
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ESWT
Arm Type
Placebo Comparator
Arm Description
Patients assigned to the ESWT group received ESWT over the plantar fascia, three days/week, for six weeks. In addition patients participated additional in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
Arm Title
Placebo
Arm Type
No Intervention
Arm Description
Routine therapy Patients participated in the same conventional stroke rehabilitation program consisting of 60 minutes of treatment a day, five times a week for six weeks (30 sessions). The conventional therapy programs were patient-specific and consisted mainly of physiotherapy, such as neurodevelopmental facilitation techniques, passive mobilization, occupational therapy, postural control exercises, stretching and range-of-motion exercises for the hemiparetic side and balance training.
Intervention Type
Device
Intervention Name(s)
ESWT
Intervention Description
extracorporeal shock wave therapy
Primary Outcome Measure Information:
Title
Balance
Description
Berg Balance Scale (BBS): The BBS is a 14-item test of functional balance, with each item rated out of 4 for a total score of 56. It assesses static balance in sitting and standing, as well as dynamic balance during transitions and while in standing. Individuals who are able to maintain their balance for each task score higher on this outcome.
Time Frame
3 mounths
Title
Maximum plantar pressure
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure maximum plantar pressure
Time Frame
3 Mounths
Title
Static posture
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure static posture
Time Frame
3 Mounths
Title
Step cycle duration
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure step cycle duration
Time Frame
3 Mounths
Title
Single-support phase
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure single-support phase
Time Frame
3 Mounths
Title
Swing phase
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure swing phase
Time Frame
3 Mounths
Title
Step length
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure step length
Time Frame
3 Mounths
Title
Foot angle
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure foot angle
Time Frame
3 Mounths
Title
Cadence
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure cadence
Time Frame
3 Mounths
Title
Gait cycle distance
Description
The Win-Track platform (MEDICAPTEURS Technology, France) is a tool used to measure
Time Frame
3 Mounths

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: First-ever hemiplegia Hemiplegia duration of at least 6 months Ability to walk alone without an orthosis. Exclusion Criteria: Patients with ataxia, dystonia, or dyskinesia Patients with dementia Patients with bilateral hemiplegia Taking antispastic drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gulnihal Deniz, Asst. Prof.
Organizational Affiliation
Firat University
Official's Role
Study Chair
Facility Information:
Facility Name
Furkan Bilek
City
Elazığ
ZIP/Postal Code
23100
Country
Turkey

12. IPD Sharing Statement

Learn more about this trial

Extracorporeal Shock Wave Therapy Applied to the Plantar Region in Individuals With Hemiplegia

We'll reach out to this number within 24 hrs